Best Biliary Tract Cancer Doctors in Chappaqua, NY

Dr. Catherine Shu isthe Price Family Associate Professor of Medicine anda board-certified medical oncologist specializing in the treatment of thoracic cancers, with a focus on lung cancer. She received her undergraduate degree from Princeton University, followed by her M.D. from Columbia University College of Physicians and Surgeons. After residency at Columbia University Medical Center, Dr. Shu completed her fellowship at Memorial Sloan Kettering Cancer Center, where she was appointed Chief Fellow. She currently serves as the Director of the Thoracic Medical Oncology Service. She has presented her work at numerous international conferences and has published in the top peer-reviewed oncology journals. She treats the entire spectrum of lung cancer, but has a particular interest in earlier stage and surgically resectable disease, specifically on drug combinations to help improve survival in this setting. Additionally, she devotes part of her research effort to patients with targetable mutations, helping to determine the best sequence of treatments. Of all her achievements, she is proudest to be able to offer individualized and compassionate care to each and every one of her patients. She understands that each patient and family carries forth a different set of beliefs, goals, and needs. Working alongside an exceptional multidisciplinary team, she is dedicated to improving the survival and bettering the quality of life of her patients.

Dr. Ryan Moy is an Assistant Professor of Medicine and medical oncologist at Columbia University Irving Medical Center where he specializes in the treatment of gastrointestinal malignancies, with a focus on esophageal and stomach cancers. He received his MD/PhD from the University of Pennsylvania and completed internship and residency training in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He then completed fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer Center and postdoctoral research at The Rockefeller University. Dr. Moy is actively involved in translational research to understand the biological mechanisms that regulate metastasis, the primary driver of mortality in gastrointestinal cancers. He has performed laboratory-based research to define critical genes that promote liver metastasis in colorectal cancer. He is also conducting research to discover key vulnerabilities in esophageal and gastric cancers, with the goal of translating these findings from the lab to develop more effective treatments for patients. As an active member of the gastrointestinal oncology and experimental therapeutics groups, Dr. Moy is involved in developing and leading clinical trials investigating novel targeted and immunotherapy treatments for esophagogastric cancer and other malignancies. His work has been recognized by several awards including a Damon Runyon Cancer Research Foundation Fellow Award and a National Cancer Institute (NCI) K08 Career Development Award. Dr. Moy works as part of a multidisciplinary team with the mission of delivering compassionate and state-of-the-art oncologic care to each patient, using a precision medicine approach to provide innovative and promising treatments.

Dr. Iwamoto is a neuro-oncologist whose previous training includes a neurology residency at NewYork-Presbyterian/Weill Cornell Medical Center and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. For over three years, Dr. Iwamoto was an attending physician and an investigator at the Neuro-oncology Branch, a trans-institute branch of the National Cancer Institute and National Institute of Neurological Disorders and Stroke, in Bethesda, MD. At the intramural NIH, Dr. Iwamoto was a principal investigator in early phase clinical trials for brain tumors and worked with laboratory and computational scientists on several translational projects in brain tumors. Dr. Iwamoto was recruited to Columbia University as the Deputy Director of the Neuro-oncology Division and is actively developing the clinical and translational research components of this program. He is an expert in the diagnosis, management, and treatment of brain and spinal cord tumors as well as neurological complications of cancer.